Evidence map›Paper›PMID 38473410›Full record

ArticleCancers2024

Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).

Sonja Aho, Emerik Osterlund, Ari Ristimäki, Lasse Nieminen, Jari Sundström, Markus J Mäkinen, Teijo Kuopio, Soili Kytölä, Annika Ålgars, Raija Ristamäki and 16 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 9 institutions in 2 countries.

Sonja AhoDepartment of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland.ORCID 0000-0002-4965-5580
Emerik OsterlundDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.ORCID 0000-0003-0973-6332
Ari RistimäkiDepartment of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, Haartmaninkatu 3, 00290 Helsinki, Finland.
Lasse NieminenDepartment of Pathology, FIMLAB, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland.
Jari SundströmDepartment of Pathology, Turku University Hospital, Kiinanmyllynkatu 4-8, 20520 Turku, Finland.
Markus J MäkinenDepartment of Pathology, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland.
Teijo KuopioDepartment of Pathology, Hospital Nova, Hoitajantie 3, 40620 Jyväskylä, Finland.ORCID 0000-0003-3503-4094
Soili KytöläDepartment of Genetics, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, Haartmaninkatu 3, 00290 Helsinki, Finland.
Annika ÅlgarsDepartment of Oncology, Turku University Hospital and University of Turku, Hämeentie 11, 20520 Turku, Finland.
Raija RistamäkiDepartment of Oncology, Turku University Hospital and University of Turku, Hämeentie 11, 20520 Turku, Finland.
Eetu HeerväDepartment of Oncology, Turku University Hospital and University of Turku, Hämeentie 11, 20520 Turku, Finland.
Raija KallioDepartment of Oncology, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland.ORCID 0000-0002-5912-496X
Päivi HalonenDepartment of Oncology, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.
Leena-Maija SoveriDepartment of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.
Arno NordinDepartment of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.ORCID 0000-0002-5446-0972
Aki UutelaDepartment of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.ORCID 0000-0003-1324-5894
Tapio SalminenDepartment of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland.
Hanna StedtDepartment of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland.
Annamarja LamminmäkiDepartment of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland.
Timo MuhonenDepartment of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.
Juha KononenDocrates Cancer Centre, Docrates Hospital, Saukonpaadenranta 2, 00180 Helsinki, Finland.
Bengt GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.ORCID 0000-0002-5440-791X
Helena IsoniemiDepartment of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.
Juho T LehtoTUNI Palliative Care Research Group, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland.ORCID 0000-0001-8519-7372
Kaisa LehtomäkiDepartment of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland.ORCID 0000-0002-2994-1459
Pia OsterlundDepartment of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland.ORCID 0000-0002-7124-3515
University of Helsinki · FITampere University · FIUniversity of Turku · FIOulu University Hospital · FIUniversity of Eastern Finland · FIUppsala University · SEDocrates Cancer Center · FIKarolinska University Hospital · SEUniversity of Jyväskylä · FI

Funding

Competitive State Research Financing of the Expert Responsibility Area of Tampere, Helsinki, Turku, Kuopio, Oulu, and Satakunta Hospitals 2012, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023Finnish Cancer Registry 2019-2020, 2021, 2022-2023Finska Läkaresällskapet 2016, 2018, 2019, 2020, 2021, 2022, 2023Helsinki University Hospital 2019, 2020, 2021, 2022, 2023Relanderin säätiö 2020-2022Tampere University Hospital Tukisäätiö 2019, 2020, 2023 and OOO-project 2020
6 · The paper itself

Abstract

The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right vs. left sided). We studied right colon vs. left colon vs. rectal PTL in a real-life study population (

Indexed as

metastasectomymetastatic colorectal cancerprimary tumor locationquality of liferesectability

Identifiers

PMID38473410
PMCPMC10931274
OpenAlexW4392460357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.